Clinical Trial Update: Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease [Phase 3]

View source ↗

Summary

Phase 3 trial comparing GA-GCB enzyme replacement therapy to imiglucerase in Type 1 Gaucher disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease Type

Drugs mentioned

• GA-GCB (Gene-Activated Human Glucocerebrosidase) (Gene-Activated® human glucocerebrosidase)
• Imiglucerase (imiglucerase)

Snippet

Sponsor: Shire | Conditions: Gaucher Disease, Type 1 | Phase 3 | Status: COMPLETED | Results posted: 2011-01-04